• 한국작물학회:학술대회논문집
• /
• 한국작물학회 1995년도 춘계 학술대회지
• /
• pp.78-79
• /
• 1995

• 한국작물학회:학술대회논문집
• /
• 한국작물학회 1996년도 추계 학술대회지
• /
• pp.120-121
• /
• 1996

• 한국약용작물학회지
• /
• 제15권3호
• /
• pp.199-202
• /
• 2007

가시오갈피에 발생하는 다양한 병해충을 분리, 동정하여 가시오갈피의 지속적인 안전재배를 위한 병 ${\cdot}$ 해충방제의 기초자료로 활용하고자 시험을 수행하였다. 가시오갈피에 발병하는 병원균을 분리동정한 결과 Phoma sp., Rhizoctonia solani, Botrytis cinerea 등 3종으로 밝혀졌으며, 병징의 특징에 따라 각각 검은무늬병, 잎마름병, 잿빛곰팡이병으로 명명하였다. 병원균에 의한 가시오갈피의 피해는 Phoma sp.에 의한 검은무늬병이 가장 컸으며, 개체별 병징의 형태나 병발생의 차이는 있었지만 6월 초부터 병반이 관찰되어 9월부터 병반면적이 30%를 넘어 계속 확대되었다. 수집균주의 배양온도별 균사생장량을 검토한 결과 균주 모두 $25^{\circ}C{\sim}30^{\circ}C$에서 생장량이 가장 많아, 여름 고온기에 많이 발생할 것으로 사료되었다. 해충별 발생시기 및 가해부위를 보면 진딧물은 6월 10일부터 관찰되어 어린 줄기를 흡즙하였고, 8월 상순에 다시 발생해 새로 분화되는 어린 화아에 집중적으로 발생하여 흡즙하였으며 노린재와 끝검은말매미충은 8월하, 6-7월에 각각 나타났으나 피해는 관찰되지 않았다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제11권3호
• /
• pp.121-127
• /
• 2007

In this study, we investigated the therapeutic effects of a novel formulation of low-dose calcium and vitamin $D_3$ blended with Rehmannia glutinosa Libosch and Eleutherococcus senticosus Max (RE+), in postmenopausal women. The controls were given either a placebo or high dose calcium and vitamin $D_3$ (Ca + D). Bone mineral density (BMD) in the L2-3 lumber spines and femur regions was assessed, and serum osteocalcin, bone-specific alkaline phosphatase (BALP), and cross-linked N-telopeptide of type I collagen (NTx) were used as markers of osteoblast and osteoclast activity. Furthermore, all variables were measured before and after 6 and 12 months of treatment. The osteocalcin level was higher in the RE+ group, and BALP was almost the same in all groups. Serum NTx was significantly decreased in the RE+ group after 12 months (p<0.05). The NTx in the Ca + D and placebo groups showed no significant change. The decrease of femur BMD was further demonstrated in the placebo group, but significantly increased in the RE+ group after 6 and 12 months of treatment (p<0.05). There were significant differences in the percent changes of femur BMD between the placebo and RE+ groups (p<0.01) and Ca+D and RE+ groups (p<0.05). The decrease of spine BMD in the placebo group was inhibited both in the Ca + D and RE+ groups, however, there was significant difference only between the placebo and RE+ groups (p<0.05). These findings suggest that continuous oral therapy of the RE+ formulation reduces rapidly decreasing bone mineral density in postmenopausal women more effectively than high doses of calcium and vitamin $D_3$ alone by inhibiting osteoclastic activity. Therefore, it seems that the RE+ has its own antiosteoporotic effects. We suggest larger clinical studies to determine the most efficacious dosage and benefits of this novel treatment.